Literature DB >> 18023719

The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression.

Chloe Milsom1, Joanne Yu, Linda May, Brian Meehan, Nathalie Magnus, Khalid Al-Nedawi, Jim Luyendyk, Jefferey Weitz, Petr Klement, George Broze, Nigel Mackman, Janusz Rak.   

Abstract

Oncogenic events play an important role in cancer-related coagulopathy (Trousseau syndrome), angiogenesis and disease progression. This can, in part, be attributed to the up-regulation of tissue factor (TF) and release of TF-containing microvesicles into the pericellular milieu and the circulation. In addition, certain types of host cells (stromal cells, inflammatory cells, activated endothelium) may also express TF. At present, the relative contribution of host- vs tumor-related TF to tumor progression is not known. Our recent studies have indicated that the role of TF in tumor formation is complex and context-dependent. Genetic or pharmacological disruption of TF expression/activity in cancer cells leads to tumor growth inhibition in immunodeficient mice. This occurred even in the case of xenotransplants of human cancer cells, in which TF overexpression is driven by potent oncogenes (K-ras or EGFR). Interestingly, the expression of TF in vivo is not uniform and appears to be influenced by many factors, including the level of oncogenic transformation, tumor microenvironment, adhesion and the coexpression of markers of cancer stem cells (CSCs). Thus, minimally transformed, but tumorigenic embryonic stem (ES) cells were able to form malignant and angiogenic outgrowths in the absence of TF. However, these tumors were growth inhibited in hosts (mice) with dramatically reduced TF expression (low-TF mice). Depletion of host TF also resulted in changes affecting vascular patterning of some, but not all types of tumors. These observations suggest that TF may play different roles growth and angiogenesis of different tumors. Moreover, both tumor cell and host cell compartments may, in some circumstances, contribute to the functional TF pool. We postulate that activation of the coagulation system and TF signaling, may deliver growth-promoting stimuli (e.g. fibrin, thrombin, platelets) to dormant cancer stem cells (CSCs). Functionally, these influences may be tantamount to formation of a provisional (TF-dependent) cancer stem cell niche. As such these changes may contribute to the involvement of CSCs in tumor growth, angiogenesis and metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023719     DOI: 10.1016/S0049-3848(07)70135-4

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  16 in total

Review 1.  PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

Authors:  Maya Zigler; Takafumi Kamiya; Emily C Brantley; Gabriel J Villares; Menashe Bar-Eli
Journal:  Cancer Res       Date:  2011-10-18       Impact factor: 12.701

Review 2.  The emerging role of exosomes in survivin secretion.

Authors:  Salma Khan; Heather Ferguson Bennit; Nathan R Wall
Journal:  Histol Histopathol       Date:  2014-07-14       Impact factor: 2.303

3.  Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis.

Authors:  Noriyuki Hirahara; Yoshitsugu Tajima; Yusuke Fujii; Shunsuke Kaji; Yasunari Kawabata; Ryoji Hyakudomi; Tetsu Yamamoto; Takahito Taniura
Journal:  Surg Endosc       Date:  2019-03-05       Impact factor: 4.584

Review 4.  Microvesicles: mediators of extracellular communication during cancer progression.

Authors:  Vandhana Muralidharan-Chari; James W Clancy; Alanna Sedgwick; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2010-05-15       Impact factor: 5.285

5.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

6.  Exosome/microvesicle-mediated epigenetic reprogramming of cells.

Authors:  Giovanni Camussi; Maria-Chiara Deregibus; Stefania Bruno; Cristina Grange; Valentina Fonsato; Ciro Tetta
Journal:  Am J Cancer Res       Date:  2010-10-22       Impact factor: 6.166

7.  Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.

Authors:  Chloe C Milsom; Joanne L Yu; Nigel Mackman; Johann Micallef; G Mark Anderson; Abhijit Guha; Janusz W Rak
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Mutant IDH1 and thrombosis in gliomas.

Authors:  Dusten Unruh; Steven R Schwarze; Laith Khoury; Cheddhi Thomas; Meijing Wu; Li Chen; Rui Chen; Yinxing Liu; Margaret A Schwartz; Christina Amidei; Priya Kumthekar; Carolina G Benjamin; Kristine Song; Caleb Dawson; Joanne M Rispoli; Girish Fatterpekar; John G Golfinos; Douglas Kondziolka; Matthias Karajannis; Donato Pacione; David Zagzag; Thomas McIntyre; Matija Snuderl; Craig Horbinski
Journal:  Acta Neuropathol       Date:  2016-09-23       Impact factor: 17.088

9.  Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo.

Authors:  Grace M Thomas; Laurence Panicot-Dubois; Romaric Lacroix; Françoise Dignat-George; Dominique Lombardo; Christophe Dubois
Journal:  J Exp Med       Date:  2009-08-10       Impact factor: 14.307

Review 10.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.